JY
CRDL

Jeff Yass’s Cardiol Therapeutics CRDL Stock Holding History

Jeff Yass’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-70,396
Closed -$89.1K – 13529
2026
Q1 		$95K Sell
70,396
-133,330
-65% -$137K ﹤0.01% 12372
2025
Q4 		$194K Buy
203,726
+110,328
+118% +$116K ﹤0.01% 10905
2025
Q3 		$99.9K Buy
93,398
+73,375
+366% +$89K ﹤0.01% 11568
2025
Q2 		$27.2K Buy
+20,023
New +$23.3K ﹤0.01% 12268
2025
Q1 		– Sell
-17,364
Closed -$22.2K – 12598
2024
Q4 		$22.2K Sell
17,364
-7,982
-31% -$13.5K ﹤0.01% 11898
2024
Q3 		$50.2K Sell
25,346
-40,834
-62% -$84.7K ﹤0.01% 11373
2024
Q2 		$134K Buy
66,180
+20,511
+45% +$43.5K ﹤0.01% 10811
2024
Q1 		$82.7K Buy
+45,669
New +$61.6K ﹤0.01% 11324
2023
Q3 		– Sell
-36,613
Closed -$32.6K – 12123
2023
Q2 		$32.6K Sell
36,613
-69,864
-66% -$46.1K ﹤0.01% 11486
2023
Q1 		$51.9K Buy
+106,477
New +$63K ﹤0.01% 11687
2022
Q4 		– Sell
-19,226
Closed -$20K – 12579
2022
Q3 		$20K Buy
19,226
+5,632
+41% +$6.87K ﹤0.01% 12600
2022
Q2 		$18K Buy
13,594
+644
+5% +$917 ﹤0.01% 12389
2022
Q1 		$20K Buy
+12,950
New +$21.4K ﹤0.01% 12617

Other funds holding CRDL

MI
MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $3.2B AUM 23.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Jeff Yass's CRDL Position: Q2 2026 in Review

Jeff Yass sold out of Cardiol Therapeutics (CRDL) in Q2 2026, closing a stake of 70,396 shares — an estimated $89.1K sold.

Jeff Yass first reported a position in CRDL in Q1 2022 and held it in 13 quarters. The position peaked at $194K in Q4 2025. 52 funds tracked by Wall St. Rank hold CRDL as of Q2 2026.

  • Jeff Yass reported no remaining Cardiol Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Jeff Yass sold 70,396 Cardiol Therapeutics shares in Q2 2026, an estimated $89.1K.
  • Jeff Yass first reported a position in Cardiol Therapeutics in Q1 2022 and held it in 13 quarters.
  • Jeff Yass's Cardiol Therapeutics position peaked at $194K in Q4 2025.
  • 52 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.